GU Cancers 2024 | Advances in theranostics for prostate cancer

Michael Hofman, FRACP, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, provides an overview of the latest developments on radionuclides used for therapy and diagnostics for patients with prostate cancer. In addition to PSMA and lutetium-177, novel radiotracers include actinium-225, lead-212 and terbium-161. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.